Barclays Upgrades IPSEN (OTCMKTS:IPSEY) to Hold

IPSEN (OTCMKTS:IPSEY) was upgraded by equities researchers at Barclays from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Other analysts have also recently issued research reports about the company. Zacks Research raised IPSEN to a “hold” rating in a report on Friday, May 29th. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, IPSEN presently has a consensus rating of “Hold”.

IPSEN Price Performance

IPSEN stock opened at $44.75 on Thursday. IPSEN has a one year low of $32.02 and a one year high of $51.10. The business has a fifty day moving average price of $46.34 and a 200-day moving average price of $46.70.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.